MYRIAD GENETICS, INC. (MYGN) Return on equity 2016–2025
MYRIAD GENETICS, INC. (MYGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-99.5%FY2025 · since FY2016: 15.8% → -99.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -99.5% | -81.3 pp |
| FY2024 | -18.1% | +15.5 pp |
| FY2023 | -33.6% | -20.9 pp |
| FY2022 | -12.6% | -9.9 pp |
| FY2021 | -2.8% | +22.6 pp |
| FY2020 | -25.4% | -25.8 pp |
| FY2019 | 0.4% | -13.4 pp |
| FY2018 | 13.8% | +11.5 pp |
| FY2017 | 2.3% | -13.6 pp |
| FY2016 | 15.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice